‘Unfortunately, everything you don't know can hurt your household. Our mission is definitely to identify the info needs of family caregivers and create powerful resources to greatly help them fill these understanding gaps. Alkermes continues to expect topline outcomes from the phase 3 study in the first half of 2014. Related StoriesNew UCL study highlights genes associated with schizophrenia and obesityResearchers examine neuroanatomical signature of schizophrenia in different ethnic groupsVraylar capsules today accepted by FDA to treat schizophrenia, bipolar disorder in adults Enrollment was completed following a prespecified interim analysis of sample size.Sam Gandy of the Mount Sinai Alzheimer’s Disease Research Center in NY said. Laurie Ryan, system director for Alzheimer’s disease clinical trials at the National Institute on Ageing, one of the National Institutes of Wellness, which funded the study.. Alnylam data files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, announced today that it has filed a Clinical Trial Application with the U.K. Medicines and Healthcare products Regulatory Agency to initiate a Stage I scientific trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin for the treatment of TTR-mediated amyloidosis .